Suchergebnisse - "Bonnet des Claustres, Mathilde"

PubPharm (7)

1

Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responses

enthalten in: The Journal of allergy and clinical immunology | 2022

von Barbieux, C. | Bonnet des Claustres, M. | Fahrner, M. | +11

CommentIn: J Allergy Clin Immunol. 2022 Apr;149(4):1210-1212. - PMID 35218769

2

Humans with inherited T cell CD28 deficiency are susceptible to skin papillomaviruses but are otherwise healthy

enthalten in: Cell | 2021

von Béziat, V. | Rapaport, F. | Hu, J. | +71

CommentIn: Cell. 2021 Jul 8;184(14):3595-3597. - PMID 34242561

3

Duality of Netherton syndrome manifestations and response to ixekizumab

enthalten in: Journal of the American Academy of Dermatology | 2021

von Barbieux, C. | Bonnet des Claustres, M. | de la Brassinne, M. | +4

4

Emerging drugs for the treatment of epidermolysis bullosa

enthalten in: Expert opinion on emerging drugs | 2020

von Titeux, M. | Bonnet des Claustres, M. | Izmiryan, A. | +2

5

Secukinumab Therapy for Netherton Syndrome

enthalten in: JAMA dermatology | 2020

von Luchsinger, I. | Knöpfel, N. | Theiler, M. | +9

CommentIn: JAMA Dermatol. 2020 Aug 1;156(8):839-841. - PMID 32459286

6

Transgenic Kallikrein 14 Mice Display Major Hair Shaft Defects Associated with Desmoglein 3 and 4 Degradation, Abnormal Epidermal Differentiation, and IL-36 Signature

enthalten in: The Journal of investigative dermatology | 2020

von Gouin, O. | Barbieux, C. | Leturcq, F. | +3

CommentIn: J Invest Dermatol. 2020 Jun;140(6):1129-1130. - PMID 32446331

7

Emerging drugs for the treatment of epidermolysis bullosa

enthalten in: Expert opinion on emerging drugs | 2020

von Titeux, M. | Bonnet des Claustres, M. | Izmiryan, A. | +2

1
[1]